维普中文期刊产品整合服务
30篇 您的检索式:作者名="SABINA A"
    题名 作者 年代 出处 被引量
1Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2°P-TIMI 50 trial显示文摘Benjamin M Scirica Marc P Bonaca Eugene Braunwald Gaetano M De Ferrari Daniel Isaza Basil S Lewis Felix Mehrhof Piera A Merlini Sabina A Murphy Marc S Sabatine Michal Tendera Frans Van de Werf Robert Wilcox David A Morrow 2012The Lancet . 2012 (9850)2012,,9850:1
2Electrode materials for ionic liquid-based supercapacitors显示文摘Catia A Sabina B Mariachiara L 2007J Power Sources2007,174,:1
3Aspects of meat quality: trace elements and B vitamins in raw and cooked meats 显示文摘Ginevra LB Sabina L Altero A 2005Journal of Food Composition and Analysis2005,18,:1
4Lentivector-me-diated RNAi efficiently suppresses prion protein and prolongs surviv-al of scrapie-infected mice显示文摘ALEXANDER P SABINA E SABA A K 2006J Clin Invest2006,116,12:1
5临床怀疑深静脉血栓形成病人的压迫超声诊断:前瞻性队列研究显示文摘目的:评价临床上怀疑为深静脉血栓形成但压迫超声显像所见正常病人不给予肝素治疗的安全性。设计:根据一种简化的程序来做压迫超声显像,超声显像的部位限于3处,即腹股沟部的股总静脉、腘静脉及胭静脉远端小腿静脉的分叉部位。初诊时超声显像为正常的病人1周后再重复检查1次。评价结果的标准:对于临床上怀疑为深静脉血栓形成的病人,凡是间隔1周两次超声显像均正常者则不予以肝素治疗,随访6个月,统计在这段时间内静脉血栓栓塞合并症的发生率。参加单位:四所大学附属医院的研究中心。结果:本研究共包括1702名病人,第一次检查发现400名血栓形成者,第二次检查又发现12名,因此用超声诊断方法在该1702名临床上怀疑为深静脉血栓形成的病人中确诊了412例,占24%。全组病人均获得随访,在两次 B 超检查之间,有1例发生了静脉血栓性栓塞的合并症,在6个月随访期间又有8例,所以累计发生率为0.7%(95%可信限为0.3%~1.2%),登门随访及补做检查的次数为平均每例0.8次。结论:对于临床上怀疑为深静脉血栓形成的病人,若连续两次压迫超声检查均为正常者,不给予肝素治疗是安全的。Alberto Cogo Anthonie W A Lensing Maria M W Koopman Franco Piovella Sergio Siragusa Philip S Wells Sabina Villalta Harry R Bller Alexander G G Turpie Paolo Prandoni 冷希圣 1998英国医学杂志中文版1998,0,1:1
6Mycoplasma genitalium among women with nongonococcal nonchlamydial pelvic inflammatory disease 显示文摘Catherine L H Patricia A T 3 Sabina GA 2006Infectious Diseases in Obstetrics and Gynecology2006,30,184:1
7Design, structure-activity relationships and in vivo charac- terization 4-amino-3-benzimidazol-2-ylhydroquinolin-2- ones:A novel class of receptor tyrosine kinase inhibitors 显示文摘Paul A Renhowe Sabina Pecchi Cynthia M Shafer 2009Journal of Medicinal Chemistry2009,52,2:1
8Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial显示文摘Gilles Montalescot Stephen D Wiviott Eugene Braunwald Sabina A Murphy C Michael Gibson Carolyn H McCabe Elliott M Antman 2009The Lancet . 2009 (9665)2009,,9665:1
9Adenine nucleotide pool perturbation is a metabolic trigger for AMP deami- nase inhibitor-based herbicide toxicity显示文摘Sabina R L Paul A L Ferl R J 2007Plant Physiol2007,143,4:1
10Changes of non-affected upper limb cortical representation in paraplegic patients as assessed by fMRI显示文摘CURT A ALKADHI H SABINA H B 2002Brain2002,125,11:1
11Meier Dietary Glutamine supplelemen-tation prevents jejunal atrophy in weaned pigs显示文摘Wu G Sabina A 1996JNutr1996,126,:1
12Comparison of B-type Natriuretic peptide levels in patients with heart failure with versus without mitral regurgitation 显示文摘Susan A James A Sabina A 2004Am J Cardiol2004,93,8:1
13TIMI myocardial perfusion grade and ST segment resolution: association with infarct size as assessed by single photon emission computed tomography imaging显示文摘Brad G Madhavi G Sabina A 2002Circulation2002,105,3:1
14Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial显示文摘Gilles Montalescot Stephen D Wiviott Eugene Braunwald Sabina A Murphy C Michael Gibson Carolyn H McCabe Elliott M Antman 2009The Lancet2009,,9665:1
15Relationship of the TIMI myocardial perfu- sion grades, flow grades, frame count, and perctaneous coronary intervention to long-term outcomes after thrombolytic administration in acute myocardial in- farction显示文摘GIBSON C M CHRISTOPHER P (2 SABINA A M 2002Circulation2002,105,:1
16Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials显示文摘Michelle L O’Donoghue Eugene Braunwald Elliott M Antman Sabina A Murphy Eric R Bates Yoseph Rozenman Alan D Michelson Raymond W Hautvast Peter N Ver Lee Sandra L Close Lei Shen Jessica L Mega Marc S Sabatine Stephen D Wiviott 2009The Lancet2009,,9694:1
17Understandings and misunderstandings of multidimensional poverty measurement显示文摘Sabina A James F 2011Journal of Economic Inequality2011,9,2:1
18普拉格雷与氯吡格雷用于拟行PCI的ST段抬高型心肌梗死患者的比较(TRITON—TIMI38):一项双盲、随机对照研究显示文摘背景对ST段抬高型心肌梗死(STEMI)患者进行采用支架的机械再灌注治疗,需要辅以阿司匹林和氯吡格雷的二联抗血小板治疗。普拉格雷是一种起效迅速的强效噻吩吡啶类药物,是氯吡格雷以外的另一种选择。本研究旨在比较拟行PCI治疗的STEMI患者应用普拉格雷与氯吡格雷的效果。方法此项双盲、随机对照研究在30个国家的707个中心进行。利用交互式语音应答系统将3534例STEMI患者随机分为两组,服用普拉格雷(负荷剂量60mg,维持剂量10mg;n=1769)或氯吡格雷(负荷剂量300mg,维持剂量75mg;n=1765)。医患双方均不了解分组情况。主要终点事件是心血管性死亡、非致死性心肌梗死或非致死性卒中。采用意向治疗方法进行疗效分析。随访15个月,在30d时进行次级分析。此研究已在Clinical Trials.gov注册,注册号为NCT00097591。结果在30d时,普拉格雷组和氯吡格雷组中出现主要终点事件的患者数分别为115例(6.5%)和166例(9.5%)(HR0.68,95%CI0.54~0.87;P=0.0017)。这一相对效果持续到15个月时[174例(10.0%)US216例(12.4%);HR0.79,95%C10.65~0.97;P:0.0221]。30d时,普拉格雷组的主要次级终点事件(心血管性死亡、心肌梗死或紧急靶血管血运重建)发生率明显较低(HR0.75,95%C10.59~0.96:P=0.0205),15个月时同样如此(HR0.79,95%C10.65—0.97;P=0.0250);普拉格雷组的支架血栓形成也明显减少。与冠状动脉搭桥(CABG)手术无关的心肌梗死溶栓(TIMI)严重出血事件,两组之间在30d(P=0.3359)和15个月(P=0.6451)时无明显差异。危及生命的TIMI严重出血以及TIMI严重或轻微出血的情况在两组间相似:普拉格雷组仅见CABG术后的TIMI严重出血显著增加(P=0.0033)。结论在拟行PCI治疗的STEMI患者中,与氯吡格雷相比,普拉格雷能更有效地预防缺血事件,而且出血风险并无明显增加。Gilles Montalescot Stephen D Wiviott Eugene Braunwald Sabina A Murphy C Michael Gibson Carolyn H McCabe Elliott M Antman 王海玲(译) 贾宁(译) 韩常宝(审校) 2009世界临床医学2009,,9:1
19Comparison of B-type natriuretic peptide levels in patients with heart failure with versus without mitral regurgitation显示文摘Susan A Mayer James A de Lemos Sabina A Murphy Sandra Brooks Brad J Roberts Paul A Grayburn 2004The American Journal of Cardiology2004,,8:1
20Aspects of meat quality: trace elements and B vitamins in raw and cooked meats显示文摘GINEVRA L B SABINA L ALTERO A 2005Journal of Food Composition and Analysis2005,18,1:1
返回顶部 每页显示:
共2页 首页 上一页 第1页 下一页 末页 /2 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费